ReviewInternational journal of cardiology. Cardiovascular risk and prevention2026
Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis.
Review in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications.Biomolecules · 2026Review
- Exercise-Based Cardiac Rehabilitation for Peripheral Artery Disease.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peripheral artery disease (PAD) reflects systemic atherosclerosis driven by dyslipidemia, particularly elevated LDL-C. Despite first-line statin therapy, many patients fail to reach lipid targets or are intolerant, necessitating alternatives. We conducted a meta-analysis to assess proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in PAD. Methods: A systematic search in PubMed, Embase, Cochrane Library, Web of Science, and Scopus was done up to August 2025. Studies evaluated effects on surrogate vascular markers [ankle-brachial index (ABI), flow-mediated dilation (FMD), carotid intima-media thickness (IMT), lipid profile] and clinical outcomes [major adverse cardiovascular events (MACE), revascularization, amputation, myocardial infarction (MI), and mortality]. Results: Six studies, assessing 6059 patients were included. PCSK9 inhibitors significantly reduced carotid IMT, LDL-C, total cholesterol, and triglycerides compared with placebo. Based on the available studies, no significant effects were observed on ABI, FMD, or HDL. Clinically, PCSK9 inhibitors lowered the risk of MACE (RR = 0.76, 95% CI [0.60-0.97]), major amputation (RR = 0.38, 95% CI [0.15-0.95]), and MI (RR = 0.63, 95% CI [0.5, 0.79]). Revascularization rates and all-cause mortality were not significant. Conclusion: PCSK9 inhibitors may provide lipid-lowering and vascular benefits in patients with PAD, reducing cardiovascular and limb events. While their impact on hemodynamic parameters and mortality remains uncertain, these findings support PCSK9 inhibitors may be effective adjunctive therapy in high-risk PAD populations. These findings support PCSK9 inhibitors may be an effective adjunctive therapy for atherosclerotic risk reduction in high-risk PAD populations. Prospective trials dedicated to limb-specific outcomes are now warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.